Cite

HARVARD Citation

    Tada, M. et al. (2019). MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells. Lung cancer. pp. 88-95. [Online]. 
  
Back to record